Trial Profile

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dubodencel (Primary) ; Filgrastim (Primary) ; Paclitaxel (Primary) ; Peginterferon alfa-2a (Primary)
Indications Haemangiosarcoma; Head and neck cancer
Focus Adverse reactions

Most Recent Events

08 Nov 2024 Planned End Date changed from 31 Dec 2029 to 5 Nov 2024.
08 Nov 2024 Planned primary completion date changed from 31 Dec 2029 to 5 Nov 2024.
08 Nov 2024 Status changed from recruiting to withdrawn prior to enrolment. (Reason the study was stopped: No participants enrolled).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com